Browse > Article
http://dx.doi.org/10.5808/gi.22012

A systemic study on the vulnerability and fatality of prostate cancer patients towards COVID-19 through analysis of the TMPRSS2, CXCL10 and their co-expressed genes  

Raza, Md. Thosif (Department of Genetic Engineering and Biotechnology, Faculty of Biological Sciences, University of Chittagong)
Mizan, Shagufta (Department of Genetic Engineering and Biotechnology, Faculty of Biological Sciences, University of Chittagong)
Publication Information
Genomics & Informatics / v.20, no.3, 2022 , pp. 31.1-31.15 More about this Journal
Abstract
A pandemic of respiratory disease named coronavirus disease 2019 (COVID-19) is caused by a novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It is reported prostate cancer patients are susceptible to COVID-19 infection. To understand the possible causes of prostate cancer patients' increased vulnerability and mortality from COVID-19 infection, we focused on the two most important agents, transmembrane protease serine subtype 2 (TMPRSS2) and the C-X-C motif 10 (CXCL10). When SARS-CoV-2 binds to the host cell via S protein-angiotensin-converting enzyme-2 receptor interaction, TMPRSS2 contributes in the proteolytic cleavage of the S protein, allowing the viral and cellular membranes to fuse. CXCL10 is a cytokine found in elevated level in both COVID-19 and cancer-causing cytokine storm. We discovered that TMPRSS2 and CXCL10 are overexpressed in prostate cancer and COVID-19 using the UALCAN and GEPIA2 datasets. The functional importance of TMPRSS2 and CXCL10 in prostate cancer development was then determined by analyzing the frequency of genetic changes in their amino acid sequences using the cBioPortal online portal. Finally, we used the PANTHER database to examine the pathology of the targeted genes. We observed that TMPRSS2 and CXCL10, together with their often co-expressed genes, are important in the binding activity and immune responses in prostate cancer and COVID-19 infection, respectively. Finally, we found that TMPRSS2 and CXCL10 are two putative biomarkers responsible for the increased vulnerability and fatality of prostate cancer patients to COVID-19.
Keywords
COVID-19; CXCL10; prostate cancer; TMPRSS2;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Thompson MR, Kaminski JJ, Kurt-Jones EA, Fitzgerald KA. Pattern recognition receptors and the innate immune response to viral infection. Viruses 2011;3:920-940.   DOI
2 Gao Y, Li T, Han M, Li X, Wu D, Xu Y, et al. Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19. J Med Virol 2020;92:791-796.   DOI
3 Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med 2020;46:846-848.   DOI
4 Lee EY, Lee ZH, Song YW. CXCL10 and autoimmune diseases. Autoimmun Rev 2009;8:379-383.   DOI
5 Peckham H, de Gruijter NM, Raine C, Radziszewska A, Ciurtin C, Wedderburn LR, et al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat Commun 2020;11:6317.   DOI
6 Chen YW, Lee MS, Lucht A, Chou FP, Huang W, Havighurst TC, et al. TMPRSS2, a serine protease expressed in the prostate on the apical surface of luminal epithelial cells and released into semen in prostasomes, is misregulated in prostate cancer cells. Am J Pathol 2010;176:2986-2996.   DOI
7 Liu K, Chen Y, Lin R, Han K. Clinical features of COVID-19 in elderly patients: a comparison with young and middle-aged patients. J Infect 2020;80:e14-e18.
8 Peng J, Sun J, Zhao J, Deng X, Guo F, Chen L. Age and gender differences in ACE2 and TMPRSS2 expressions in oral epithelial cells. J Transl Med 2021;19:358.   DOI
9 Schuler BA, Habermann AC, Plosa EJ, Taylor CJ, Jetter C, Negretti NM, et al. Age-determined expression of priming protease TMPRSS2 and localization of SARS-CoV-2 in lung epithelium. J Clin Invest 2021;131:e140766.   DOI
10 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394-424.   DOI
11 Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus: a first step in understanding SARS pathogenesis. J Pathol 2004;203:631-637.   DOI
12 Howard EE, Margolis LM, Berryman CE, Lieberman HR, Karl JP, Young AJ, et al. Testosterone supplementation upregulates androgen receptor expression and translational capacity during severe energy deficit. Am J Physiol Endocrinol Metab 2020;319: E678-E688.   DOI
13 Lucas JM, Heinlein C, Kim T, Hernandez SA, Malik MS, True LD, et al. The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. Cancer Discov 2014;4:1310-1325.   DOI
14 Lucas JM, True L, Hawley S, Matsumura M, Morrissey C, Vessella R, et al. The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma. J Pathol 2008;215:118-125.   DOI
15 Hoang T, Nguyen TQ, Tran TA. Genetic susceptibility of ACE2 and TMPRSS2 in six common cancers and possible impacts on COVID-19. Cancer Res Treat 2021;53:650-656.   DOI
16 Kalkanli A, Kirkik D, Bostanci E, Tas SK. The important role of TMPRSS2 gene in COVID-19 and prostate cancer: in silico approach. Braz Arch Biol Technol 20021;64:11.
17 Zhang T, Tseng C, Zhang Y, Sirin O, Corn PG, Li-Ning-Tapia EM, et al. CXCL1 mediates obesity-associated adipose stromal cell trafficking and function in the tumour microenvironment. Nat Commun 2016;7:11674.   DOI
18 Rezaei-Tavirani M, Rezaei-Taviran S, Mansouri M, Rostami-Nejad M, Rezaei-Tavirani M. Protein-protein interaction network analysis for a biomarker panel related to human esophageal adenocarcinoma. Asian Pac J Cancer Prev 2017;18:3357-3363.
19 Ren S, Wei GH, Liu D, Wang L, Hou Y, Zhu S, et al. Whole-genome and transcriptome sequencing of prostate cancer identify new genetic alterations driving disease progression. Eur Urol 2018;73:322-339.   DOI
20 Qiu J, Chen K, Zhong C, Zhu S, Ma X. Network-based protein-protein interaction prediction method maps perturbations of cancer interactome. PLoS Genet 2021;17:e1009869.   DOI
21 Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012;2:401-404.   DOI
22 Boyer JL. The comparative toxicogenomics database: a cross-species resource for building chemical-gene interaction networks. Toxicol Sci 2006;92:587-595.   DOI
23 Koster J, Volckmann R, Zwijnenburg D, Molenaar P, Versteeg R. Abstract 2490: R2: Genomics analysis and visualization platform. Cancer Res 2019;79(13 Suppl):2490.   DOI
24 Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020;395:507-513.   DOI
25 Satue-Gracia EM, Vila-Corcoles A, de Diego-Cabanes C, Vila-Rovira A, Torrente-Fraga C, Gomez-Bertomeu F, et al. Susceptibility and risk of SARS-CoV-2 infection among middle-aged and older adults in Tarragona area, Spain. Med Clin (Barc) 2022;158:251-259.   DOI
26 Hoffmann M, Kleine-Weber H, Schroeder S, Kruger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181:271-280.   DOI
27 Chen L, Liu B, Yang J, Jin Q. DBatVir: the database of bat-associated viruses. Database (Oxford) 2014;2014:bau021.   DOI
28 Ejaz H, Alsrhani A, Zafar A, Javed H, Junaid K, Abdalla AE, et al. COVID-19 and comorbidities: deleterious impact on infected patients. J Infect Public Health 2020;13:1833-1839.   DOI
29 Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020;21:335-337.   DOI
30 Kanda N, Shimizu T, Tada Y, Watanabe S. IL-18 enhances IFN-gamma-induced production of CXCL9, CXCL10, and CXCL11 in human keratinocytes. Eur J Immunol 2007;37:338-350.   DOI
31 Vahidy FS, Pan AP, Ahnstedt H, Munshi Y, Choi HA, Tiruneh Y, et al. Sex differences in susceptibility, severity, and outcomes of coronavirus disease 2019: cross-sectional analysis from a diverse US metropolitan area. PLoS One 2021;16:e0245556.   DOI
32 Mjaess G, Karam A, Aoun F, Albisinni S, Roumeguere T. COVID-19 and the male susceptibility: the role of ACE2, TMPRSS2 and the androgen receptor. Prog Urol 2020;30:484-487.   DOI
33 Mollica V, Rizzo A, Massari F. The pivotal role of TMPRSS2 in coronavirus disease 2019 and prostate cancer. Future Oncol 2020;16:2029-2033.   DOI
34 Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 2020;130:2620-2629.   DOI
35 Liu Y, Zhang C, Huang F, Yang Y, Wang F, Yuan J, et al. Elevated plasma levels of selective cytokines in COVID-19 patients reflect viral load and lung injury. Natl Sci Rev 2020;7:1003-1011.   DOI
36 ElGohary GM, Hashmi S, Styczynski J, Kharfan-Dabaja MA, Alblooshi RM, de la Camara R, et al. The risk and prognosis of COVID-19 infection in cancer patients: a systematic review and meta-analysis. Hematol Oncol Stem Cell Ther 2020 Jul 30 [Epub]. https://doi.org/10.1016/j.hemonc.2020.07.005.   DOI
37 Johannesen TB, Smeland S, Aaserud S, Buanes EA, Skog A, Ursin G, et al. COVID-19 in cancer patients, risk factors for disease and adverse outcome, a population-based study from Norway. Front Oncol 2021;11:652535.   DOI
38 Ragab D, Salah Eldin H, Taeimah M, Khattab R, Salem R. The COVID-19 cytokine storm: what we know so far. Front Immunol 2020;11:1446.   DOI
39 Ioannidis JP, Axfors C, Contopoulos-Ioannidis DG. Population-level COVID-19 mortality risk for non-elderly individuals overall and for non-elderly individuals without underlying diseases in pandemic epicenters. Environ Res 2020;188:109890.   DOI
40 Gwak J, Jeong H, Lee K, Shin JY, Sim T, Na J, et al. SFMBT2-mediated infiltration of preadipocytes and TAMs in prostate cancer. Cancers (Basel) 2020;12:2718.   DOI
41 Arora K, Barbieri CE. Molecular subtypes of prostate cancer. Curr Oncol Rep 2018;20:58.   DOI
42 Losuwannarak N, Maiuthed A, Kitkumthorn N, Leelahavanichkul A, Roytrakul S, Chanvorachote P. Gigantol targets cancer stem cells and destabilizes tumors via the suppression of the PI3K/AKT and JAK/STAT pathways in ectopic lung cancer xenografts. Cancers (Basel) 2019;11:2032.   DOI
43 Bhowmick NA, Oft J, Dorff T, Pal S, Agarwal N, Figlin RA, et al. COVID-19 and androgen-targeted therapy for prostate cancer patients. Endocr Relat Cancer 2020;27:R281-R292.   DOI
44 Montopoli M, Zumerle S, Vettor R, Rugge M, Zorzi M, Catapano CV, et al. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532). Ann Oncol 2020;31:1040-1045.   DOI
45 Shimizu M. Clinical features of cytokine storm syndrome. In: Cytokine Storm Syndrome (Cron RQ, Behrens EM, eds.). Cham: Springer International Publishing, 2019. pp. 31-41.
46 Chandrashekar DS, Bashel B, Balasubramanya SA, Creighton CJ, Ponce-Rodriguez I, Chakravarthi B, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia 2017;19:649-658.   DOI
47 Murdoch C, Giannoudis A, Lewis CE. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 2004;104:2224-2234.   DOI
48 Alassaf E, Mueller A. The role of PKC in CXCL8 and CXCL10 directed prostate, breast and leukemic cancer cell migration. Eur J Pharmacol 2020;886:173453.   DOI
49 Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res 2020;48:W509-W514.   DOI
50 Tang Z, Kang B, Li C, Chen T, Zhang Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res 2019;47:W556-W560.   DOI
51 Szklarczyk D, Morris JH, Cook H, Kuhn M, Wyder S, Simonovic M, et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res 2017;45:D362-D368.   DOI
52 Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA 2020;323:2052-2059.   DOI
53 Salunke AA, Nandy K, Pathak SK, Shah J, Kamani M, Kottakota V, et al. Impact of COVID-19 in cancer patients on severity of disease and fatal outcomes: a systematic review and meta-analysis. Diabetes Metab Syndr 2020;14:1431-1437.   DOI
54 Faria NR, Suchard MA, Rambaut A, Streicker DG, Lemey P. Simultaneously reconstructing viral cross-species transmission history and identifying the underlying constraints. Philos Trans R Soc Lond B Biol Sci 2013;368:20120196.   DOI
55 Wightman SC, Uppal A, Pitroda SP, Ganai S, Burnette B, Stack M, et al. Oncogenic CXCL10 signalling drives metastasis development and poor clinical outcome. Br J Cancer 2015;113:327-335.   DOI
56 Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395: 1054-1062.   DOI
57 Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis 2020;20:533-534.   DOI
58 Luis AD, Hayman DT, O'Shea TJ, Cryan PM, Gilbert AT, Pulliam JR, et al. A comparison of bats and rodents as reservoirs of zoonotic viruses: are bats special? Proc Biol Sci 2013;280:20122753.
59 Lau SK, Li KS, Huang Y, Shek CT, Tse H, Wang M, et al. Ecoepidemiology and complete genome comparison of different strains of severe acute respiratory syndrome-related Rhinolophus bat coronavirus in China reveal bats as a reservoir for acute, self-limiting infection that allows recombination events. J Virol 2010;84: 2808-2819.   DOI
60 Turnquist C, Ryan BM, Horikawa I, Harris BT, Harris CC. Cytokine storms in cancer and COVID-19. Cancer Cell 2020;38:598-601.   DOI
61 Han HJ, Wen HL, Zhou CM, Chen FF, Luo LM, Liu JW, et al. Bats as reservoirs of severe emerging infectious diseases. Virus Res 2015;205:1-6.   DOI
62 Rodriguez-Morales AJ, Bonilla-Aldana DK, Balbin-Ramon GJ, Rabaan AA, Sah R, Paniz-Mondolfi A, et al. History is repeating itself: probable zoonotic spillover as the cause of the 2019 novel coronavirus epidemic. Infez Med 2020;28:3-5.
63 Spinelli A, Pellino G. COVID-19 pandemic: perspectives on an unfolding crisis. Br J Surg 2020;107:785-787.   DOI
64 Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, et al. Comorbidity and its impact on patients with COVID-19. SN Compr Clin Med 2020;2:1069-1076.   DOI
65 Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARSCoV-2: a systematic review and meta-analysis. Int J Infect Dis 2020;94:91-95.   DOI
66 Benton DJ, Wrobel AG, Xu P, Roustan C, Martin SR, Rosenthal PB, et al. Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion. Nature 2020;588:327-330.   DOI
67 Fuentes-Prior P. Priming of SARS-CoV-2 S protein by several membrane-bound serine proteinases could explain enhanced viral infectivity and systemic COVID-19 infection. J Biol Chem 2021;296:100135.   DOI
68 Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.   DOI
69 O'Shea TJ, Cryan PM, Cunningham AA, Fooks AR, Hayman DT, Luis AD, et al. Bat flight and zoonotic viruses. Emerg Infect Dis 2014;20:741-745.   DOI
70 Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 2020;579:270-273.   DOI